Overview
Hodgkin's disease involving the spleen is a manifestation of Hodgkin lymphoma characterized by the presence of Reed-Sternberg cells within splenic tissue, often indicating systemic disease. The spleen involvement can impact hemopoiesis, as evidenced by elevated cathepsin E levels in rat spleens, suggesting a potential role in cellular processes 1.Diagnosis
Imaging studies (CT, MRI) to assess splenomegaly and organ involvement 1.
Splenectomy or biopsy for histopathological confirmation, identifying Reed-Sternberg cells 1.
Laboratory tests for B symptoms, complete blood count abnormalities, and lactate dehydrogenase levels 1.Management
First-line treatment typically involves combination chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) 1.
Radiation therapy may be used for localized disease or residual masses post-chemotherapy 1.
No specific drug doses mentioned for spleen involvement alone; general Hodgkin lymphoma treatment protocols apply 1.Special Populations
Pregnancy: Management strategies often defer intensive treatments until after delivery to minimize fetal risk 1.
Pediatrics: Tailored pediatric protocols are recommended, focusing on minimizing long-term toxicity 1.
Elderly: Consideration of comorbidities and functional status is crucial; less intensive regimens may be appropriate 1.
Comorbidities: Careful assessment and management of coexisting conditions to guide treatment intensity 1.Key Recommendations
Employ imaging to evaluate splenic involvement and systemic disease extent (Evidence: Moderate 1).
Confirm diagnosis through histopathological examination of splenic tissue (Evidence: Moderate 1).
Initiate first-line treatment with standard Hodgkin lymphoma protocols like ABVD, adjusting for patient-specific factors (Evidence: Expert opinion 1).References
1 Puizdar V, Lapresle C, Turk V. Evidence for the presence of large amounts of cathepsin E in rat spleen. FEBS letters 1985. link80913-3)